Renasant Bank Buys Shares of 41,897 Pfizer Inc. $PFE

Renasant Bank bought a new position in shares of Pfizer Inc. (NYSE:PFE) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 41,897 shares of the biopharmaceutical company’s stock, valued at approximately $1,016,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GKV Capital Management Co. Inc. acquired a new position in Pfizer in the 1st quarter worth $27,000. Curio Wealth LLC increased its holdings in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares during the last quarter. Bayforest Capital Ltd bought a new stake in shares of Pfizer in the 1st quarter valued at about $28,000. Harbor Asset Planning Inc. bought a new stake in Pfizer in the second quarter valued at approximately $29,000. Finally, WPG Advisers LLC bought a new stake in Pfizer in the 1st quarter valued at $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 4.5%

PFE stock opened at $25.49 on Wednesday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The business has a 50-day simple moving average of $24.75 and a 200 day simple moving average of $24.41. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a market cap of $144.93 billion, a PE ratio of 13.56, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research analyst reports. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $26.00 price objective on shares of Pfizer in a report on Wednesday, November 5th. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a research report on Friday, October 31st. Finally, Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $28.18.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.